Identification of a system required for the functional surface localization of sugar binding proteins with class III signal peptides in Sulfolobus solfataricus

The hyperthermophilic archaeon Sulfolobus solfataricus contains an unusual large number of sugar binding proteins that are synthesized as precursors with a class III signal peptide. Such signal peptides are commonly used to direct archaeal flagellin subunits or bacterial (pseudo)pilins into extracellular macromolecular surface appendages. Likewise, S. solfataricus binding proteins have been suggested to assemble in higher ordered surface structures as well, tentatively termed the bindosome. Here we show that S. solfataricus contains a specific system that is needed for the functional surface localization of sugar binding proteins. This system, encoded by the bas (bindosome assembly system) operon, is composed of five proteins: basABC, three homologues of so-called bacterial (pseudo)pilins; BasE, a cytoplasmic ATPase; and BasF, an integral membrane protein. Deletion of either the three (pseudo)pilin genes or the basEF genes resulted in a severe defect of the cells to grow on substrates which are transported by sugar binding proteins containing class III signal peptides, while growth on glucose and maltose was restored when the corresponding genes were reintroduced in these cells. Concomitantly, ΔbasABC and ΔbasEF cells were severely impaired in glucose uptake even though the sugar binding proteins were normally secreted across the cytoplasmic membrane. These data underline the hypothesis that the bas operon is involved in the functional localization of sugar binding proteins at the cell surface of S. solfataricus. In contrast to surface structure assembly systems of Gram-negative bacteria, the bas operon seems to resemble an ancestral simplified form of these machineries.

The disulphide isomerase DsbC cooperates with the oxidase DsbA in a DsbD-independent manner

In Escherichia coli , DsbA introduces disulphide bonds into secreted proteins. DsbA is recycled by DsbB, which generates disulphides from quinone reduction. DsbA is not known to have any proofreading activity and can form incorrect disulphides in proteins with multiple cysteines. These incorrect disulphides are thought to be corrected by a protein disulphide isomerase, DsbC, which is kept in the reduced and active configuration by DsbD. The DsbC/DsbD isomerization pathway is considered to be isolated from the DsbA/DsbB pathway. We show that the DsbC and DsbA pathways are more intimately connected than previously thought. dsbA - dsbC - mutants have a number of phenotypes not exhibited by either dsbA - , dsbC - or dsbA - dsbD - mutations: they exhibit an increased permeability of the outer membrane, are resistant to the lambdoid phage φ80, and are unable to assemble the maltoporin LamB. Using differential two-dimensional liquid chromatographic tandem mass spectrometry/mass spectrometry analysis, we estimated the abundance of about 130 secreted proteins in various dsb - strains. dsbA - dsbC - mutants exhibit unique changes at the protein level that are not exhibited by dsbA - dsbD - mutants. Our data indicate that DsbC can assist DsbA in a DsbD-independent manner to oxidatively fold envelope proteins. The view that DsbC's function is limited to the disulphide isomerization pathway should therefore be reinterpreted.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/72894/1/MMI_6030_sm_Tables_S1-S4.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/72894/2/MMI_tables_s1-s4.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/72894/3/j.1365-2958.2007.06030.x.pd

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

En studie i behandlingsarbete med barn med ADHD och deras familjer vid BUP-mottagningar i Göteborg

ADHD är en förkortning för Attention-Deficit/Hyperactivity Disorder som innebär neuro¬psykiatriska problem med hyperaktivitet, ouppmärksamhet och bristande impulskontroll. Socialstyrelsen (2002) beräknar att 3-5 procent av barn och unga lider av denna svårighet. En mindre andel av dessa får hjälp och behandling via barnpsykiatrin. Studien avser att ge en beskrivning och analys av den barnpsykiatriska icke medicinska personalens, psykologer och socionomers, sätt att arbeta och tänka kring behandlingsarbete med ADHD-barn och deras familjer. Inledningsvis försöker jag dels beskriva ADHD diagnostiskt och vilka problem det kan medföra, men också sätta in problematiken i ett sammanhang utifrån BUP:s arbetsmetoder, behandlingsforskning och behandlingserfarenheter. Jag har valt att göra en kvalitativ intervjuundersökning. Undersökningsgruppen består av fem behandlare inom barn och ungdomspsykiatri inom BUP:s öppenvård i Göteborg. Tre är leg. psykologer och leg. psykoterapeuter och två är socionomer och leg. psykoterapeuter. Undersöknings¬deltagarna berättar om sammanlagt åtta fall. Utifrån fallbeskrivningar har jag kopplat frågeställningar om hur diagnosen inverkar på metod och vilken problematik man valt arbeta med och teoretiska och metodmässiga utgångspunkter. Resultatet visar att det finns en stor enighet om att föräldraarbetet oftast är avgörande för att behandlingen med barnet ska få effekt. Fallen uppvisar en stor komplexitet med både familjeproblem och komorbiditet hos barnet. Det visar sig att behandlarna utgår i behandlingen från barnets och familjens helhetssituation, inte ADHD-symptomen primärt. ADHD-diagnosen blir därför inte avgörande för metodvalet. Många barn med ADHD kommer inte till behandling på BUP. I uppsatsens slutdiskussion diskuteras därför olika faktorer som inverkar på beslut om erbjudande om behandlingsinsats. Några idéer om ett behandlingsupplägg skisseras

Genetics of extracellular protein secretion by Gram-negative bacteria

International audienc

Genetics of extracellular protein secretion by Gram-negative bacteria

International audienc